| The continual reassessment method in cancer phase I clinical trials: a simulation study. | |
| | |
MedLine Citation:
|
PMID: 8210815 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In cancer studies, the aim of phase I clinical trials is to identify an appropriate dose for experimentation in phase II and III studies. The continual reassessment method (CRM) has been developed recently and presented as the method of choice in the design and analysis of such phase I studies. However, to implement the method, some methodological and practical considerations must be addressed. This paper examines, through a simulation study, the sensitivity of CRM both to the initial modelling of the dose-toxicity relationship and the prior. It appears that the performance of CRM can be improved by using vague priors and initial tuning of the model to allow flexibility. |
| | |
Authors:
|
S Chevret |
Related Documents
:
|
18605475 - The prep statistic as a measure of confidence in model fitting. 15860765 - Increasing the degrees of freedom in existing group randomized trials: the df* approach. 10473845 - On the directionality of cortical interactions studied by structural analysis of electr... 15078495 - On the evolution of statistical methods as applied to clinical trials. 19000965 - A-optimality orthogonal forward regression algorithm using branch and bound. 3298315 - Fluorescence resonance energy transfer measurements of distances in actin and myosin. a... |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Statistics in medicine Volume: 12 ISSN: 0277-6715 ISO Abbreviation: Stat Med Publication Date: 1993 Jun |
Date Detail:
|
Created Date: 1993-11-01 Completed Date: 1993-11-01 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8215016 Medline TA: Stat Med Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 1093-108 Citation Subset: IM |
Affiliation:
|
Département de Biostatistique et Informatique Médicale, Hôpital Saint-Louis, Paris, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
administration & dosage*,
adverse effects,
toxicity Bayes Theorem Bias (Epidemiology) Clinical Trials, Phase I as Topic* / methods, standards Dose-Response Relationship, Drug Ethics, Medical Evaluation Studies as Topic Humans Logistic Models Models, Statistical* Monte Carlo Method Neoplasms / drug therapy*, epidemiology Organizational Objectives Research Design* Sensitivity and Specificity |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The nephritogenic T lymphocyte response in interstitial nephritis.
Next Document: On population and individual bioequivalence.